But John Stanford, a shareholder in the company and a researcher at University College London, says these studies were poorly designed and analyzed. When he and collaborators re-analyzed the results, they found that Mycobacterium injections could increase survival of adenocarcinoma patients by four months. Stanford believes that part of the bacterial cell wall switches the body from producing ineffective antibodies to sending out cancer-killing blood cells.
In the second study, researchers reported that 60 renal cancer patients injected with Myobacterium survived just as long as those treated with standard chemotherapy.
Stanford has formed a company, Immodulon Therapeutics, and wants to run trials with a stricter and more intense injection regime, to repeat the results and, hopefully, extend patients' lives longer.
Although both Krieg and Timmerman are inspired by Coley's work, they question the philosophy behind reviving Coley's preparation and using other bacterial extracts. But, Krieg says, "as a physician you have to maintain a sense of humility and avoid being overly skeptical."